Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

Tara M Babu,Xiaoying Shen,R Scott McClelland,Zijun Wang,Stacy Selke,Chloe Wilkens,Kirsten A Hauge,Christopher L McClurkan,Erin Goecker,Kerry J Laing,David M Koelle,Alexander L Greninger,Michel C Nussenzweig,David C Montefiori,Lawrence Corey,Anna Wald
DOI: https://doi.org/10.1093/ofid/ofad673
2024-01-03
Open Forum Infectious Diseases
Abstract:Abstract We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the neutralizing antibody response of a new vaccination regimen against the Omicron (Omicron) sub - variants of the SARS - CoV - 2. Specifically, the researchers examined whether this heterologous vaccination regimen, which consists of an initial two - dose vaccination with Novavax's recombinant nanoparticle protein vaccine NVX - CoV2373 followed by a single - dose Pfizer - BioNTech monovalent mRNA booster vaccine BNT162b2, can effectively generate a long - lasting neutralizing antibody response against the Omicron BA.4/BA.5 and BA.1 variants, and explored its immune evasion situation against the XBB.1.5 variant. The main objectives of the study include: 1. **Evaluating immunogenicity**: By detecting the level of neutralizing antibodies, evaluate whether this heterologous vaccination regimen can trigger an effective immune response. 2. **Persistence analysis**: Observe whether this immune response can remain stable within 6 months after the booster shot. 3. **Comparing the neutralizing ability of different variants**: Compare the neutralizing antibody titers of different Omicron sub - variants (such as BA.1, BA.4/BA.5 and XBB.1.5) to understand the effectiveness of the vaccine against these variants. 4. **Memory B - cell and T - cell responses**: Evaluate whether this vaccination regimen can induce a long - lasting response of memory B - cells and T - cells, thereby providing more long - term protection. Through these studies, the authors hope to provide a scientific basis for future vaccination strategies, especially when dealing with emerging new variants, on how to select the most effective vaccine combinations to improve the immunity of the population.